Why the study?
Acute MR after AMI is a life-threatening complication historically treated with medical therapy or surgery, but evidence is growing for the benefits of transcatheter edge-to-edge repair.
What is the current role of transcatheter edge-to-edge repair (TEER) in patients with acute mitral regurgitation following acute myocardial infarction?
What is the current role of transcatheter edge-to-edge repair (TEER) in patients with acute mitral regurgitation following acute myocardial infarction?
TEER is emerging as a safe and effective alternative to medical therapy or surgery for the management of life-threatening acute mitral regurgitation following acute myocardial infarction.
Acute post-AMI MR signals high mortality risk warranting urgent assessment; review leaves optimal strategies open for prospective trials.
Acute mitral regurgitation (MR) is not a rare finding following acute myocardial infarction (AMI). It may develop due to papillary muscle rupture (primary MR) or due to rapid remodeling of the infarcted areas leading to geometric changes and leaflets tethering (secondary or functional MR). The clinical presentation can be catastrophic, with pulmonary edema and refractory cardiogenic shock. Acute MR is a potentially life-threatening complication and is linked to worse clinical outcomes. Until recently, medical treatment or mitral valve surgery were the only established treatment options for these patients. However, there is growing evidence for the benefits of safe and effective trans-catheter interventions in this condition, specifically transcatheter edge-to-edge repair (TEER). We aimed to review the current role of TEER in post-MI acute MR patients, focusing on different etiologies.
No takes yet. Share an insight, caveat, or question.
Haberman et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: